Cargando…
Balancing early access with uncertainties in evidence for drugs authorized by prospective case series – systematic review of reimbursement decisions
AIMS: To review clinical and cost‐effectiveness evidence underlying reimbursement decisions relating to drugs whose authorization mainly is based on evidence from prospective case series. METHODS: A systematic review of all new drugs evaluated in 2011–2016 within a health care profession‐driven reso...
Autores principales: | Wallerstedt, Susanna M., Henriksson, Martin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5980547/ https://www.ncbi.nlm.nih.gov/pubmed/29381234 http://dx.doi.org/10.1111/bcp.13531 |
Ejemplares similares
-
Pre-reimbursement: early assessment for coverage decisions
por: Grössmann, Nicole, et al.
Publicado: (2019) -
Assessment of the clinical and cost-effectiveness evidence in the reimbursement decisions of new cancer drugs
por: Chauca Strand, G., et al.
Publicado: (2022) -
Access to innovative drugs and the National Reimbursement Drug List in China: Changing dynamics and future trends in pricing and reimbursement
por: Macabeo, Bérengère, et al.
Publicado: (2023) -
Drug pricing and reimbursement decision making systems in Mongolia
por: Dorj, Gereltuya, et al.
Publicado: (2017) -
Orphan drugs’ clinical uncertainty and prices: Addressing allocative and technical inefficiencies in orphan drug reimbursement
por: Eichler, Hans-Georg, et al.
Publicado: (2023)